When herpes simplex virus was inoculated into the flank of a BALB/c mouse by scarification, the local replication of virus was followed by the establishment of an acute ganglionic infection. The subsequent centrifugal spread of this virus along nerves to the skin of the whole dermatome led to the development of a bandlike "zosteriform" rash. This represents a highly reproducible system in which virus travels through the nervous system synchronously in large numbers of animals. The transection of peripheral nerves at various times after infection showed that the virus had completed the round trip 60 h after inoculation into the upper flank and was detectable as infectious virus by 74 h postinfection. After the administration of virus, neutralizing but not nonneutralizing antibodies prevented the development of the zosteriform rash. The target epitopes of the protective antibodies were not confined to a single glycoprotein. Neutralizing antibody was effective even when given up to 60 h postinfection and was protective even when administered after sensory neurotomy at this time. Antibody was therefore able to prevent clinically and virologically detectable infection of the skin, presumably by acting peripherally on virus emerging from nerve endings. A quantitative estimate of the action of one of the neutralizing monoclonal antibody preparations, AP7, showed that high titers (several times higher than those normally found in immune mice) were needed to prevent this type of infection. These results are discussed in relation to antibody prophylaxis.
The role of immunity in modifying the course of both primary and recurrent herpes simplex virus infection has received considerable attention in recent years (15) . The paradoxical occurrence of recrudescent lesions in humans in the face of immunity, often with no detectable rise in circulating neutralizing antibodies (5), leads one to address the question of whether specific immune processes can play any significant role in the prevention of recurrent disease.
We have recently described a model for investigating the mechanisms of immunity in experimental herpes (23) . The infection of mice in the flank led to the development of ganglionic infection, and the subsequent delivery of virus to the skin of the whole dermatome, by nerve fibers. Mice infected in this way develop a band-like "zosteriform" rash several days after the initial inoculation of virus, a phenomenon first noticed by Teague and Goodpasture in 1923 (25) . The significance of this model is that the epidermal cells distant from the inoculation site become infected from nerve endings, a process which also occurs during the development of a recrudescent lesion. Although in our model system no reactivation has preceded the delivery of virus to the skin, the peripheral events can be used to study the action of immunological effector mechanisms on the prevention or modulation of infection in the epidermis after centrifugal spread of virus from the ganglion.
We report here the results of further studies in this system, investigating the effect of antibodies on the development and course of zosteriform lesions. The possibility that antibodies may indeed be able to prevent recrudescence is discussed in the context of existing knowledge.
MATERIALS AND METHODS
Mice. Female inbred BALB/c mice, raised in the department animal house, were used throughout. They were infected at 6 to 8 weeks of age.
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Virus. A well-characterized clone of a recent oral isolate of herpes simplex virus type 1, strain SC16 (7), was grown in BHK-21 cells and stored in samples at -70°C until required.
Inoculation of mice. The left flank was clipped and depilated with Nair (Carter-Wallace Ltd., Folkestone, United Kingdom). The mice were then lightly anesthetized with ether and inoculated with 5 x 104 PFU of virus, as previously described (23) .
Removal of tissue and infectious virus assay. Tissue samples from the inoculation site and lower flank were taken separately as previously described (23 intensity was read at 410 nm. The antibodies gave a binding titer of 1:100 or greater in this test.
Neurotomy. Sensory denervation of the left flank was performed through a posterior midline incision as previously described (23) . The animals were anesthetized with intraperitoneal diazepam and fentanyl. Control animals received a similar operation without division of the nerves.
RESULTS
The effect of neutralizing monoclonal antibody AP7 on the recovery of virus from the skin. The relevant properties of AP7 are summarized in Table 1 . A sample of 100 RIl of this antibody was administered intravenously to five groups of three mice on day 1 postinfection, resulting in serum neutralizing titers in excess of 1:200 in each animal. Groups were killed daily, and the skin of the inoculation site and lower flank of each mouse was separately tested for the presence of infectious virus. The titers were compared with controls that received saline instead of AP7 (Fig. 1) . The administration of AP7 on day 1 had no significant effect on the amount of virus recovered from the inoculation site on days 2 and 3 postinfection. However, although high titers of virus were isolated from the lower flank of controls on days 4 and 5, no virus was found at this site in antibody-treated groups. This corresponded with a failure of the antibodytreated mice to develop zosteriform rashes.
Comparison of various monoclonal antibodies. Five monoclonal antibodies, each with different properties, and polyclonal hyperimmune serum were screened for the ability to prevent zosteriform spread when administered on day 1 postinfection. The results are indicated in Table 1 , along with the properties of each antibody. The only property that correlated with the ability of an antibody to prevent virus spread was the ability to neutralize virus in vitro. Quantitation of the protective effect of one of the neutralizing monoclonal antibodies, AP7, is discussed below.
Time at which infectious virus can be detected in the lower flank. Virus can be consistently found remote from the inoculation site on day 3 postinfection (23). We have analyzed the timing of this event more precisely (Fig. 2) . Groups of 10 mice were screened at 2-h intervals, from 68 to 76 h postinfection, for the presence of infectious virus in the lower flank. Virus was not found in any mice at 68 h postinfection but by 74 h, all of the mice in the group were positive. Delay of antibody administration. The effect of delaying the administration of antibody (AP7) was also investigated. Groups of 10 mice received antibody at various times postinfection and were examined for the appearance of zosteriform rashes on day 5. AP7 was effective when administered at 54 and 60 h postinfection, after which (at 66 h postinfection and when no antibody was used) its protective effect was lost.
Precise time at which virus arrives in lower flank. It has been previously shown that sensory neurotomy before infection of the flank prevents zosteriform spread (23) because virus is denied access to the nervous system. It was also shown that, with the nerves intact, virus was demonstrable in the sensory ganglia 48 h postinfection. By the division of sensory nerves to the flank at various times after infection (from 48 h onwards), we were able to estimate the time at which virus makes the return trip to the periphery (Table 2) .
Control mice underwent a similar operation, except that the nerves were left intact. The results indicate that from 60 h postinfection onwards, virus was peripherally located (i.e., in the flank) because at this time neurotomy no longer prevented the development of the zosteriform rash, which appeared between days 4 and 5, in synchrony with controls.
Antibody after nerve section. To demonstrate that an entirely peripheral action of AP7 was sufficient to suppress the formation of the zosteriform rash, additional groups of mice from the previous experiment received AP7 immediately after sensory neurotomy ( also examined for the appearance of lesions on day 5, compared with the group that received the operation but no antibody. As previously indicated, at 60 h postinfection, neurotomy alone did not prevent the development of rashes. However, antibody was shown to be effective at this time; AP7 thus remained highly effective at 60 h postinfection, even though it was given after the nerves were cut. Amount of AP7 required. The ability of AP7 to prevent the formation of the zosteriform lesion when given before infection and at 24 and 48 h postinfection was quantified in terms of the serum neutralization titer that had to be achieved (Fig.  3) . At each time point, 100 ,ul of diluted ascitic fluid was given to each mouse. Groups of five mice were studied, and control mice received saline. Serum neutralization titers were determined 60 h postinfection. The results clearly indicate that high titers of AP7 were required to neutralize the infection. DISCUSSION Zosteriform spread of herpes simplex virus, as indicated by the appearance of infectious virus distant from the inoculation site, occurred by 74 h postinfection. Therefore, since the bandlike rash caused by the centrifugal spread of virus includes the site of inoculation, it must be assumed that virus recovered from this site after 74 h is not entirely the result of local replication. This fact must be taken into account when studying agents that accelerate the clearance of virus from the skin. In such instances, an apparent reduction in local virus growth may well result from an inhibition of the zosteriform component without necessarily acting directly on infected peripheral cells. This was found to be the case with the neutralizing antibody AP7, in which zosteriform spread was completely inhibited by intravenous antibody given 24' h postinfection. However, at the inoculation site, early replication (uncomplicated by zosteriform spread) was not significantly different in antibody-treated and control groups.
It has been shown that antibodies are generally unable to affect cell-to-cell spread of herpes simplex virus in infected tissue culture monolayers (9). Our results indicate that this may also be the case in vivo, after an infection in the (4, 27) . In any case, the presence of a high level of antibodies does not apply to primary infection. Virus reaches the ganglia early (24 to 48 h postinfection [4, 11, 14, 16] ), long before a detectable antibody response has occurred.
Most workers agree that T-cells are required for the clearance of virus from established sites of infection (reviewed by Nash and Wildly [15] ), although there remains a possibility that antibody-mediated killing of infected cells plays a supportive role (1, 2, 21, 22 ). We have, so far, failed to show in vivo that any of the antibodies described in this report can increase the already effective T-cell-mediated clearance of virus from the skin (unpublished data). Antibody alone is not sufficient to cause virus clearance in the absence of T-cell mechanisms either in vitro (16) or in vivo (11) , although clinical disease can be delayed (11) .
In recurrent disease, virus reactivates in the presence of antibody, both naturally in humans (3, 5, 24) and in experimental models (8, 20) . It therefore appears that normally acquired levels of antibodies are insufficient to prevent recurrent ganglionic infection and, in many instances, recrudescent skin lesions. Our results agree that antibodies are of limited value in clearing virus from the skin in primary and recurrent infection; however, our results suggest that a heightened immune response may be able to interrupt the process of epidermal infection which must occur before a recrudescent lesion can appear. Therapy for various clinical presentations of herpetic infection is anxiously sought. The possibility that high-titer monoclonal antibodies might be useful in prophylaxis against the lethal herpetic infections seen in the immunocompromised host is intriguing and deserves further investigation. In addition, the more common recurrent epidermal infections lead to misery and discomfort for many millions worldwide. The recent suggestion that vaccines may both protect against primary disease and reduce the frequency and severity of recrudescent lesions (G. Skinner, personal communication) has aroused considerable interest. It is possible that such protection could result from an elevated (qualitative rather than quantitative) antibody response, leading to protection mediated by the mechanism described here. Certainly, it is apparent that there is a need for further investigation into the immunotherapy of herpes simplex virus infections.
